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ABSTRACT
Messenger RNAs containing premature stop cod-
ons are generally targeted for degradation through
nonsense-mediated mRNA decay (NMD). This mech-
anism degrades aberrant transcripts derived from
mutant genes containing nonsense or frameshift
mutations. Wild-type genes also give rise to tran-
scripts targeted by NMD. For example, some wild-
type genes give rise to alternatively spliced
transcripts that are targeted for decay by NMD. In
Caenorhabditis elegans, the ribosomal protein (rp)
L12 gene generates a nonsense codon-bearing
alternatively spliced transcript that is induced in an
autoregulatory manner by the rpL12 protein. By
pharmacologically blocking the NMD pathway, we
identified alternatively spliced mRNA transcripts
derived from the human rpL3 and rpL12 genes that
are natural targets of NMD. The deduced protein
sequence of these alternatively spliced transcripts
suggests that they are unlikely to encode funct-
ional ribosomal proteins. Overexpression of rpL3
increased the level of the alternatively spliced rpL3
mRNA and decreased the normally expressed
rpL3. This indicates that rpL3 regulates its own pro-
duction by a negative feedback loop and suggests the
possibility that NMD participates in this regulatory
loop by degrading the non-functional alternatively
spliced transcript.
INTRODUCTION
Nonsense-mediated mRNA decay (NMD) is a post-
transcriptional pathway that recognizes and rapidly degrades
mRNA that contains a premature termination codon (PTC)
in its open reading frame (ORF) (1), thereby preventing the
synthesis of truncated proteins that could be deleterious to the
cell. NMD is evolutionarily conserved in all organisms tested,
from yeast to humans (2). The NMD process is well under-
stood in yeast, where it is believed to take place in the cyto-
plasm (3). Cis-acting elements required for PTC recognition
include degenerate AU-rich sequences positioned downstream
from the PTC (4). Although conforming to the same general
strategy as in yeast, there are some relevant differences in the
NMD process in higher eukaryotes. Namely, in mammalian
cells NMD can occur either in the cytoplasm or in association
with the nucleus (5), and is triggered when a stop codon lies
>55 nt upstream from an exon-exon junction (6,7). The posi-
tions of exon junctions are marked on the mRNA by an exon
junction complex (EJC) which is deposited 20–24 nt upstream
from exon-exon junctions and is exported to the cytoplasm
together with the spliced mRNA (8). A physiological stop
codon has no downstream EJC, whereas a PTC is followed
by at least one EJC (9).
The genetics of NMD has been studied in Saccaromyces
cerevisiae and Caenorhabditis elegans. Three yeast (Upf1–
Upf3) (10,11) and seven C.elegans (smg1–7) (12,13) genes
are known to play an essential role in NMD. The smg2, smg3
and smg4 proteins, which are orthologues of the S.cerevisiae
Upf1, Upf2 and Upf3 proteins, respectively, have been char-
acterized (14). Homologues of yeast Upf proteins have been
identified also in mammalian cells and their ability to direct
aberrant mRNA to NMD has been established (15). However,
NMD in higher eukaryotes seems to require a larger number
of protein factors and a more complex regulation. In fact,
the smg1 protein has not been found in yeast, whereas it is
involved in NMD in C.elegans and human cells (16).
NMD has been largely studied as a control mechanism that
prevents the production of potentially deleterious polypeptides
resulting from a mutation in the DNA of germ or somatic cells,
or as a result of inefficient splicing during post-transcriptional
processing (17,18). However, besides counteracting aberrant
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gene expression, NMD has been implicated in the regulation
of normal gene expression (19,20).
Mitrovich and Anderson (20) showed that unproductive
mRNA isoforms for four ribosomal proteins, rpL3, rpL7a,
rpL10a and rpL12, accumulate in C.elegans mutants that
lack a component of the NMD pathway. They also demon-
strated that in transgenic worms overexpressing rpL12, a
greater proportion of endogenous rpL12 transcript is spliced
unproductively. These results indicated that rpL12 autoregu-
lates its splicing and prompted the concept that one of the
functions of NMD surveillance might be to eliminate RNA
by-products of gene regulation. Mitrovich and Anderson (21)
subsequently extended the surveillance role of NMD in
C.elegans to transcripts of expressed pseudogenes that encode
a small nucleolar RNA (snoRNA). This observation suggested
that these transcripts could represent an evolutionary interme-
diate between snoRNA-encoding host genes that do or do not
encode proteins. Alternatively spliced transcripts containing
premature termination codons appear to be widespread in
mammals, based on analysis of human EST databases (22).
Interestingly, 11 ribosomal genes, including human rpL3,
rpL10a and rpL12, were predicted to generate aberrant
mRNAs.
In this study, we directly examined whether human ribo-
somal genes give rise to alternatively spliced transcripts sub-
ject to NMD. Towards this aim, we analyzed the expression
pattern of the rpL3-, rpL7a-, rpL10a- and rpL12-encoding
genes. This led to the identification of alternatively spliced
nonsense codon-bearing transcripts from the rpL3 and rpL12
loci. We showed that these transcripts are degraded byNMD and
we uncovered an autoregulatory mechanism that appears to
regulate the level of the alternatively spliced rpL3 transcript.
MATERIALS AND METHODS
Cell culture and transfection conditions
The human lung carcinoma Calu-6 cell line (ATCC, HTB 56;
ICLC, HTL97003) was cultured in DMEM containing 10%
fetal bovine serum (FBS) with 2 mM L-glutamine and 0.1 mM
non-essential amino acids. Cells were grown to 80–90% con-
fluence and then treated with 100 mg/ml cycloheximide for
4 h or with 20 mM wortmannin for 2 h.
The rat PC12 (pheochromocytoma cells) Tet-Off cell line
(Clontech) was grown in DMEM supplemented with 5% fetal
calf serum (FCS), 10% horse serum, 2 mM L-glutamine and
100 mg/ml G418 (Invitrogen). For stable transfection of these
cells, 15 mg of pTRE2-hyg/HA-L3 or pTRE2-hyg/HA-L12
expression plasmids were transfected with lipofectAMINE
Reagent, according to the manufacturer’s instructions (Invit-
rogen). After transfection for 24 h, cells were incubated in
fresh medium containing 200 mg/ml hygromycin (USB) and
10 ng/ml doxycycline (Sigma). Resistant clones were isolated
15–20 days later and expanded for further analyses. The
expression of HA-L3 or HA-L12 was induced upon removal
of doxycyclin. For NMD blockage, drug treatment was used as
described above.
Origin of probes
The GAPDH probe was purchased from Clontech. The p53
probe was derived from a plasmid generously provided by
Dr F. Esposito. The rpL3 and rpL12 cDNA probes were
generated by RT–PCR of total RNA extracted from HeLa
cells, using the SuperScript One-Step RT–PCR kit and gene-
specific oligonucleotides. The intronic specific probes,
containing the retained region in alternative transcripts, were
derived from PCR amplification on the alternative transcript
cDNA, using the primer pair 50-CTCCGCTCGGCTCTG-
CCC-30 (forward) and 50-CTTCAGGAGCAGAGCAGA-30
(reverse, Int3R) for rpL3 intron 3 (see Figure 1B); 50-GTG-
CGTGCTCTGGTTGTG-30 (forward, Int1F) and 50-CCTA-
GGGCGTGCGGGCTC-30 (reverse) for rpL12 intron 1 (see
Figure 3B). The HA (50-AAGAGCGTAATCTGGAACAT-
CGTATGGGTACAT-30) and rpL3 30-untraslated region
(30-UTR) (50-ATTTTATTGATGAGACCCCACCAGCTGC-
ACAAAGTACTCCTGGCA-30) probes were automatically
synthesized.
Northern and western blot analyses
Total RNA was extracted using TRIzol reagent (Invitrogen),
following the manufacturer’s recommendations. Equal
amounts (20 mg) of RNA were resolved in a 1.5% (for rpL3
and p53 analysis) or 1.7% (for rpL12 analysis) agarose-
formaldehyde gels and transferred to a nylon membrane
(Millipore). Hybridations with radiolabeled probes were per-
formed as described by Church and Gilbert (23). The relative
amount of RNA loaded per lane was normalized to that
of GAPDH. cDNA probes were 32P-labeled by random prim-
ing using [a-32P]dCTP. Oligonucleotide probes were 50 end-
labeled with phage T4 polynucleotide kinase (Roche) and
[g-32P]ATP. Signals were detected using a STORM 860
PhosphorImager and quantified using ImageQuant software
v5.0 (Molecular Dynamics). Protein samples (100 mg/lane)
were subjected to 10% SDS–PAGE and transferred to a
nitrocellulose membrane (Schleicher & Schuell). HA-tagged
proteins were revealed with the rabbit HA-probe (Y-11) poly-
clonal antibody (Santa Cruz Biotechnology) and peroxidase-
conjugated horseradish anti-rabbit antibody (Amersham
Biosciences). An enhanced chemiluminescence (ECL) system
(Amersham Biosciences) was used for detection.
Plasmid construction
The 50-UTR of the human rpL3 gene fused to the HA-tag
was cloned as double-strand oligonucleotide in the pTRE2-
Hyg inducible expression vector (Clontech) to generate the
pTRE2-Hyg/HA plasmid. The rpL3 and rpL12 ORFs were
RT–PCR amplified from HeLa RNA and cloned in pTRE2-
Hyg/HA to obtain the pTRE2-Hyg/HA-L3 and pTRE2-Hyg/
HA-L12 constructs. All recombinant plasmids were verified
by sequencing.
RT–PCR analysis and sequencing
To identify the human alternative transcripts, RT–PCRs were
performed using the primers shown in Figures 1B and 3B. Total
RNA extracted from Calu-6 cells was treated with RQ1-
Rnase-free DNaseI (Promega) to eliminate any genomic
DNA and RT was carried out on 25 mg of RNA using the
antisense oligonucleotides Int3R and Ex2R (50-CAGGGCA-
GAAGTGGCACC-30) to synthesize the rpL3 and rpL12
cDNA fragments, respectively, and Superscript II RT (Invit-
rogen) according to the manufacturer’s instructions. The PCR
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amplifications were performed according to standard proced-
ures. In brief, alternative cDNA products were amplified for
35 cycles, with annealing at 54C (for rpL3 amplification) or
58C (for rpL12 amplification), using the primer couples Ex3F
(50-GGGCATTGTGGGCTACGT-30)/Int3R for rpL3 and
Ex2R/Int1F for rpL12.
To identify the mouse rpL12 alternative transcript, a
RT–PCR was performed as described above, using RNA
extracted from heart tissue and the following primer couple:
mInt1F (50-GTGCGTGCCCTCGCCGCG-30)/mEx2R (50-
CAGACCCAGAGGACCGAT-30) (see Figure 5B). The
annealing step in the amplification reaction was performed
Figure 1. Identification of NMD sensitive isoforms of the human rpL3. (A) Analysis of p53 and rpL3 expression in Calu-6 cells after incubation with CHX (4 h) or
wortmannin (Wort.) (2 h). Total RNA purified from treated or untreated cells was hybridized with the cDNA specific probes as indicated. The size of canonical
mRNA is indicated; rpL3-a indicates the newly identified isoform. The quantity of RNA was normalized using a GAPDH-specific probe. A representative result
of three independent experiments is shown. (B) Nucleotide sequence of rpL3 intron 3 with 50 flanking exonic sequences. Lower case letters refer to intronic
nucleotides; upper case letters refer to exonic nucleotides. The intronic sequence retained by alternative splicing is indicated in bold. The primers used for
RT–PCR are underlined. Canonical and alternative splice sites (GT/AG), as determined by sequence analysis of RT–PCR products, are shown in bold upper case
letters and indicated by 50 or 30 arrows. The ORF of exonic and retained intronic sequences is shown. Nucleotides encoding the PTC are boxed and shaded in gray. The
nucleotide positions according to the corresponding NCBI/GenBank sequences (accession no.: AL022326) is indicated. (C) Left panel RT–PCR assays of RNA
from Calu-6 cells. Amplifications were performed with the following primers: lane 1, Ex3F/Int3R (rpL3-specific); lane 2, reaction was carried out as in lane 1 but
omitting the RT step. As negative control, amplification was performed without cDNA (lane 3). The base pairs of HinfII-digested pUC18 (lane M) are indicated on the
left. Right panel, schematic drawing of alternative splicing of human rpL3; intron 3 and flanking exons 3 and 4 (E3, E4) are shown.
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at 50C. PCR products were resolved on ethidium
bromide-stained 2% agarose gels, and analyzed by dideoxy
sequencing.
Sequence analysis and comparison
Sequences of rp genes were aligned using the CLUSTAL W
algorithm (24), then adjusted manually. Sequence identity for
the individual rpL3 introns and exons was established by using
the web-based EMBOSS infoalign program.
RESULTS
Blockade of NMD upregulates alternatively
spliced rp transcripts
To determine whether the mammalian rpL3, rpL7a, rpL10
and rpL12 genes give rise to alternatively spliced transcripts
containing premature termination codons, we exploited the
observation that NMD-regulated mRNAs accumulate in cells
exposed to NMD-blocking drugs. In this study, we used wort-
mannin, an inhibitor of the human smg1 kinase (16), cyclo-
heximide (CHX), an inhibitor of protein synthesis that
represses NMD (25), and the human cell line Calu-6 (26) in
which a nonsense mutation in the p53 gene results in the
production of a PTC-containing mRNA that is an NMD sub-
strate (16). Total RNA was prepared from drug-treated and
non-treated cells and analyzed in northern blotting experi-
ments. As shown in Figure 1A, the aberrant p53 mRNA
was barely detectable in non-treated cells, and very pro-
nounced in treated cells, which is consistent with the obser-
vations made by Yamashita et al. (16). Having shown that
NMD was blocked, we examined whether rp transcripts were
induced. While we did not detect induction of alternative
human rpL10a nor rpL7a transcripts, we did observe a novel
1.5 kb rpL3 transcript induced by cycloheximide and
wortmannin. In fact, like the aberrant p53 mRNA, this
minor species was barely detectable in untreated cells and
very pronounced in treated cells (Figure 1A). In contrast,
the level of the canonical 1.3 kb rpL3 mRNA was not affected
by these treatments, as its level was virtually unchanged, as
occurs for the control GAPDH transcript (Figure 1A). We
named the alternative rpL3 transcript ‘rpL3-a’.
NMD-substrate transcripts of rp genes are generated by
alternative splicing events that lead to retention of
intronic sequences
As indicated above, some human rp genes have been predicted
to produce NMD-candidate mRNA isoforms (22). More spe-
cifically, three alternative mRNA isoforms of the rpL3 gene
have been predicted to contain a PTC, one of which includes
a putative transcript that has a molecular size larger than the
canonical (i.e. productive) mRNA. In such a case, the use of
the proposed splice sites would result in an alternative mRNA
isoform that retains some intronic sequences from intron 3.
In an attempt to obtain experimental proof of this predicted
alternative mRNA isoform, we evaluated whether rpL3-a
mRNA accumulates in treated cells. For this purpose,
we examined the rpL3 gene using RT–PCR analysis with
Calu-6 RNA as template, and primers flanking the proposed
alternatively spliced intron (Figure 1B). After amplifications,
a cDNA species was detected (Figure 1C, left panel), thereby
providing experimental evidence that alternative splicing had
occurred within the candidate intron of rpL3.
Sequencing analysis of the RT–PCR product revealed the
site of the splicing event that caused the retention of a portion
of the intron. In detail, 30 alternative splicing in intron 3 of
rpL3 generated a larger transcript that retained the 30-most
180 nt of the intron (Figure 1B, also see schematic representa-
tion in Figure 1C, right panel). The size of the alternative
mRNA species is consistent with the apparent molecular
size of the NMD-sensitive mRNA species identified for
rpL3 (Figure 1A). Inclusion of the alternatively spliced region
led to the generation of an in-frame translation termination
codon in the rpL3 transcript localized >50–55 nt upstream
from the 30-most exon-exon junction. The latter feature char-
acterizes PTCs responsible for conveying the aberrant mRNA
to the NMD pathway.
A DNA probe spanning sequences from the rpL3 intron 3
retained by alternative splicing, and thus specific for the
alternative isoform, was hybridized to RNA extracted from
Calu-6 cells treated or not with NMD-blocking drugs and
fractionated on agarose gel. As shown in Figure 2A (left
panel), in the presence of drugs, the specific probe revealed
an mRNA species, whose size and accumulation mode were
identical to those of the NMD-sensitive isoform shown in
Figure 1A. The levels of this mRNA are shown in the panel
on the right.
Upon withdrawal of CHX and wortmannin, the rpL3-a
mRNA decreased progressively and reached a (low) steady-
state level in 6 h, whereas the canonically spliced mRNA was
unaffected by drug removal (Figure 2B). These findings con-
firm that the alternative transcript is NMD substrate. In fact,
it accumulates consequent to NMD block, and is rapidly
degraded upon NMD restoration.
An NMD candidate mRNA larger than the canonical
mRNA has also been predicted for the rpL12 gene (22).
In this case, alternative splicing of the primary transcript
leads to retention of some intron 1 sequences. We thus
looked for NMD-targeted rpL12 mRNA isoforms using the
same experimental strategy described for rpL3. In a northern
analysis, an rpL12 cDNA probe revealed a major mRNA spe-
cies of 0.63 kb in untreated as well as in cells treated with
NMD-blocking drugs, and a minor species of an apparent size
of 0.8 kb, which accumulated after NMD inhibition (rpL12-a
in Figure 3A). An intron 1 probe specifically detected the
NMD-sensitive mRNA isoform (Figure 3A). An RT–PCR
experiment (data not shown) with Calu-6 cell RNA as tem-
plate, and primers flanking intron 1 followed by sequencing
analysis of the amplification product identified the start site
of the splicing event: a 50 alternative splicing in intron 1 of
rpL12 generated an mRNA isoform that contained 210 bp of
the 50 region of the intron (Figure 3B and C).
In summary, the human rpL12 and rpL3 genes generated
two alternative mRNAs: a canonical transcript that is not
affected by NMD, and an isoform produced by alternative
splicing that results in incomplete removal of introns 3 and
1, respectively (see schematic representation in Figures 1C and
3C). The alternative splicing introduces PTCs, and the
stability of these transcripts increases when NMD-mediated
degradation is inhibited.
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rpL3 and rpL12 alternative splicing is conserved among
mammalian species
Alternative splicing transcripts of these genes could result
from a systematic error of the splicing machinery. Alternat-
ively, non-canonical splicing could be functionally relevant
for gene expression, and thus regulated to modify the level of
the functional ribosomal protein. To test these hypotheses we
investigated whether alternative splicing of the type observed
in human cells occurs in other organisms. To this aim, we
compared the sequences of the human affected introns with the
introns of orthologue genes from other eukaryotes.
Using the CLUSTAL W algorithm, we aligned the sequence
of human rpL3 intron 3 with each intron in the C.elegans and
Drosophila melanogaster rpL3 genes, and with the corres-
ponding intron in the murine and bovine rpL3 genes. While
we found a low degree of sequence identity between C.elegans
and D.melanogaster rpL3 introns, there was a high degree
of sequence identity in rpL3 intron 3 in mammals (Figure 4A).
In particular, the early portion of the intron (2144–2557 nt)
shows a sequence identity of about 50%, whereas the remain-
ing 30 region (2558–2762 nt) is nearly identical (nucleotide
identity of about 90%) in the three species. This region con-
tains the alternatively spliced sequence corresponding to
2583–2762 nt. Thus, the portion of the intron retained by
alternative splicing in the human rpL3 mRNA isoform is
more conserved than the portion excised.
To determine whether this degree of conservation applied
to other introns of the gene, we compared the whole intron–
exon sequence of the rpL3 gene in human, bovine and rodent
species. As expected, exon sequences are highly conserved,
the nucleotide identity ranging from 80 to 90%, whereas intron
Figure 2. Expression of alternatively spliced mRNA of the rpL3 gene (rpL3-a mRNA). (A) Left panel: northern blots of total RNA from untreated Calu-6 cells
and from the same cells after incubation with either CHX or Wort. The probe used for hybridization is specific for the portion of intron retained by alternative
splicing. Right panel: rpL3-a mRNA was quantified by PhosphorImager, normalized to GAPDH levels and expressed in a graph as a ratio to endogenous levels
in untreated cells. Numerical values are the average of three independent experiments, reported with SDs. (B) Decay of the drug-stabilized rpL3-a mRNA. Total
RNA was isolated from Calu-6 cells before treatment (lane C), after treatment with CHX or with Wort., and 2 and 6 h after drug removal. Northern blot was performed
with the indicated probes.
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sequences have a more complex pattern of conservation
(Figure 4B). In fact, the average sequence identity shared
by human and bovine introns is 50%; this identity reaches
60% for the snoRNA-encoding introns 1, 5 and 7. A putative
snoRNA coding sequence has also been identified in intron 3
of rpL3; however, it does not appear to be expressed and,
moreover, the highly conserved region is significantly longer
than the putative snoRNA sequence (27). Thus, no other intron
sequence appears to be as conserved as the intron 3 region that
is affected by alternative splicing. The pattern of conservation
Figure 3. Identification and expression of an alternatively spliced isoform of human rpL12 gene. (A) Left panel: northern blot analysis of rpL12 expression in Calu-6
cells after incubation with CHX (4 h) or Wort. (2 h). Total RNA purified from treated or untreated cells was hybridized with the cDNA specific probes as indicated.
The size of canonical mRNA is indicated; rpL12-a indicates the newly identified isoform. The quantity of RNA was normalized using a GAPDH-specific probe.
A representative result of three independent experiments is shown. Right panel: rpL12-a mRNA was quantified by PhosphorImager, normalized to GAPDH
levels and expressed in a graph as a ratio to endogenous levels in untreated cells. Numerical values are the average of three independent experiments, reported with
SDs. (B) Nucleotide sequence of rpL12 intron 1 with 50 or 30 flanking exonic sequences. Lower case letters refer to intronic nucleotides; upper case letters refer to
exonic nucleotides. The intronic sequence retained by alternative splicing is indicated in bold. The primers used for RT–PCR are underlined. Canonical and
alternative splice sites (GT/AG), as determined by sequence analysis of RT–PCR products, are shown in bold upper case letters and indicated by 50 or 30 arrows. The
ORF of exonic and retained intronic sequences is shown. Nucleotides encoding the PTC are boxed and shaded in gray. The nucleotide positions according to
the corresponding NCBI/GenBank sequences (accession no. NT_008470 ) is indicated. (C) Schematic drawing of alternative splicing of rpL12; the two first exons
(E1 and E2) and the first intron are shown.
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Figure 4. (A) Sequence comparison of the rpL3 alternatively spliced intron among mammals. Nucleotide sequences of human, bovine and mouse intron 3 (hInt3,
bInt3 and mInt3, respectively) are aligned. Conserved residues are shaded in gray; the region retained by alternative splicing is underlined. The numbers on
right of sequences indicate the nucleotide positions of the human rpL3 gene according to the corresponding GenBank sequences. Accession nos of sequences
(NCBI/GenBank): AJ238851 and NT_039621 for bovine and mouse genes, respectively; for the human gene, refer to the legend to Figure 1 (the arrowhead
indicates the alternative splice site). (B) Comparative analysis of rpL3 introns among mammals. The numbers indicate the percent nucleotide identity of human
sequences compared to the mouse and bovine genes. For intron 3, the nucleotide identity of the portions retained and excised by alternative splicing is
indicated.
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is even more interesting when we compare the human and
mouse genes. In fact, although the average sequence identity
of introns is lower (30%), reaching 50% only for introns
5 and 7, which, in analogy with the human and bovine
rpL3 genes, could contain snoRNAs, the region of intron 3
retained after alternative splicing is, again, highly conserved
(90% identity). Moreover, it is noteworthy that the whole
mouse intron 3 appears to be more conserved than any
other intron (58%).
We next searched EST databases for cDNA sequences
containing the region of interest. We found that several
cDNA clones of Mus musculus and Bos taurus EST (e.g.
accession nos CA574552, AW761943, AV612606 etc.)
contain sequences spanning 2583–2762 nt of the human
intron 3.
Taken together, the foregoing results indicate that: (i) the
sequence of alternatively spliced rpL3 intron is under strong
selective pressure, the retained portion being conserved
as well as the exons; (ii) the type of alternative splicing
described in the human gene appears to be conserved
among mammals.
We conducted a similar sequence analysis of alternatively
spliced intron 1 of the human rpL12 gene. The exon–intron
organization of this gene is known for fewer organisms. How-
ever, while the bovine and human sequences of rpL12 intron 1
share a 70% identity, the mouse sequence appears much
less conserved. In fact, we found that the human intron 1 is
larger than the corresponding intron in the mouse gene, and
sequence conservation is restricted to a few short regions
(Figure 5A). However, a BLAST search in the mouse EST
database performed with the mouse intron sequence as a query
revealed that several expressed sequences contain the 50-most
121 nt of intron 1. Furthermore, using a RT–PCR strategy
(Figure 5B) similar to that described above for human rp
genes, we identified a mouse alternative cDNA containing
this region. Thus, alternative splicing occurs in the 50 region
of intron 1 in the mouse rpL12 gene as well as in the human
counterpart. Sequence analysis of the alternative transcript
demonstrated that, unlike the human rpL12 and rpL3 altern-
ative isoforms in which PTCs occur in the retained intron
sequences, in the mouse alternative rpL12 transcript the partial
retention of intron 1 results in a frame-shift that introduces
a PTC in the downstream exon 3 (Figure 5B). Notably, the 50
alternative splice site in the mouse rpL12 gene is located at
exactly the same position as in the human gene, and in a highly
conserved region (Figure 5A).
The levels of rpL3 expression regulate
the alternative splicing
Our demonstration that rpL3 and rpL12 alternative splicing is
conserved among mammals strongly suggested that this event
is not simply the result of a post-transcriptional processing
error, but it could serve to regulate ribosomal protein expres-
sion levels. In fact, because the alternative splicing generates
an unproductive mRNA isoform, the cellular level of a func-
tional ribosomal protein might be correlated to the regulation
of this event. To address this issue, we evaluated whether the
amount of the rpL3-generated protein affects the splicing pat-
tern of the rpL3 gene. We used PC12 Tet-Off cells to induce
overexpression of the protein. Cells were stably transfected
with a vector containing the human rpL3 coding sequence
fused to the hemagglutinin (HA) epitope coding sequence,
and a hygromycin selection marker. Total cell lysates from
20 hygromycin-resistant clones were analyzed 48 h after
removal of doxycyclin by western blotting with an HA-
specific antibody to monitor the production of HA-L3 protein,
and clones with the highest expression level were selected.
Time course analysis of the two most inducible clones (L3–8
and L3–9), at both RNA and protein level, demonstrated that
the expression peaks 24 h after the removal of doxycycline
(data not shown).
In these experiments, total RNA was prepared from control
cells (PC12) and from L3–8 and L3–9 clones, with or without
doxycycline, each under drug-treatment and non-treatment
conditions, and then analyzed by northern blotting
(Figure 6A). The same filter was sequentially hybridized with:
(i) an oligonucleotide probe specific for the HA-tag, which
detects exogenous HA-L3 mRNA; (ii) the intron probe, which
only detects the alternative transcript; and (iii) a probe specific
for the 30-UTR of rpL3 cDNA, which distinguishes the endo-
genous canonical transcript from the exogenous transcript.
The amount of each mRNA species was quantified by
PosphorImager analysis (Figure 6B). The expression of the
HA-L3 protein was evaluated by western blot analysis on
protein extracts from the same cells using an HA antibody
(aHA in Figure 6A). As expected, in both clones, exposure to
CHX and the consequent block of translation reduced the
amount of exogenous protein.
In control cells (Figure 6A, lanes 1–3), endogenous rpL3
mRNAs reacted in the same fashion as they did in Calu-6 cells,
which indicates that the alternative splicing described for the
human rpL3 gene is conserved in rat cells. In fact, the amount
of canonical mRNA was the same in treated and untreated
cells, whereas the steady-state amount of alternatively spliced
mRNA was very low in the absence of drugs and increased
after incubation with wortmannin (3-fold) and even more
so after incubation with CHX (9-fold), thus demonstrating
that this transcript is stabilized by NMD inhibition. As expec-
ted, a similar pattern of expression occurred in clones L3–8
(lanes 4–6) and L3–9 (lanes 10–12) when the transcription of
exogenous HA-L3 cDNA was inhibited by the addition of
doxycycline.
The induction of the HA-L3 protein (lanes 7–9 and 13–15)
resulted in relevant differences in the expression levels of both
canonical and alternative rpL3 transcripts. In fact, the increase
in the alternative isoform was greater in cells in which NMD
was blocked than in control cells and in non-induced clones,
which suggests that the HA-L3 protein and drugs exert an
additive effect on the levels of this mRNA. Interestingly, in
cells not exposed to the NMD-inhibiting drug, the overexpres-
sion of the protein was associated with accumulation of the
alternative transcript. In addition, the expression of the exo-
genous HA-L3 protein was associated with a relevant decrease
(50%) of the amount of canonical mRNA. This effect was
drug-independent (lanes 8, 9, 14 and 15) and absent in non-
induced clones (lanes 4–6 and 10–12). These results demon-
strate that the down-regulation of canonical rpL3 mRNA is
related to the expression of the exogenous protein. Moreover,
clone L3–8, which expressed the highest amount of HA-L3
at both RNA and protein level, had the largest increase of the
alternative transcript and the largest decrease of canonical
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mRNA. Consequently, we conclude that the pattern of splic-
ing is regulated by exogenous HA-L3 in a dose-dependent
manner.
To determine whether this regulation is specifically medi-
ated by rpL3, we evaluated whether alternative splicing of
the rpL3 gene is affected by overexpression of a different
ribosomal protein, i.e. rpL12. We selected stable transfectants
inducible for the expression of the HA-tagged rpL12 and
measured by northern blotting, the expression of canonical
rpL3 and of the alternatively spliced rpL3 transcript when
rpL12 was overexpressed. We found no significant change
in the expression of the canonical rpL3 mRNA or in
Figure 5. Conservation of alternative splicing in the mammalian rpL12 gene. (A) Sequence comparison between human intron 1 (hInt1) and the corresponding
bovine (bInt1) and mouse intron (mInt1). The arrowhead indicates the alternative splice site. (B) Nucleotide sequence of mouse rpL12 intron 1 with the 50 and
30 flanking exonic sequences. Refer to Figure 4 for alignment; accession nos of sequences (NCBI/GenBank): NT_039206 for mouse gene, NW_619058 for bovine
gene; for the human gene, refer to the legend to Figure 3.
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accumulation of the alternative NMD-sensitive isoform in
HA-L12 overexpressing cells (Figure 6A, right panel). We
thus concluded that the alternative splicing of the rpL3
gene is regulated by its own protein product.
DISCUSSION
NMD is an mRNA surveillance mechanism that leads to
selective degradation of PTC-containing mRNA transcripts
arising from somatic mutations or errors in gene expression.
Figure 6. Effect of overexpression of r-proteins on the rpL3 splicing pattern. (A) Analysis of rpL3 expression in control cells (PC12) and in clones stably transfected
with HA-tagged rpL3 cDNA (L3–8 and L3–9) or with HA-tagged rpL12 cDNA (L12). Northern blot hybridizations of total RNA were performed with the indicated
probes. Protein samples purified from the same clones were analyzed by western blotting with an HA-tag specific antibody (aHA). (B) Quantification of mRNAs
shown in panel A. The amounts of HA-mRNA are expressed in arbitrary units after normalization to GAPDH mRNA levels. The mRNA levels of endogenous
isoforms were normalized to GAPDH and expressed as a ratio to endogenous levels in untreated control cells. (+), addition of doxycycline; (), removal of
doxycycline. The average of three independent experiments is shown, with SDs.
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Considerable light has been shed on the molecular mechanism
by which, in vivo, NMD eliminates aberrant mRNAs to pre-
vent the production of harmful polypeptides [for reviews see
(7,25,28–30)]. In contrast, little is known about the substrates
of mRNA surveillance in wild-type organisms. Mitrovich
and Anderson (20) demonstrated, in C.elegans, that ribosomal
protein alternative transcripts, which are natural targets of
NMD, arise not through errors but through feedback regula-
tion of splicing triggered by the protein product. In humans, an
extensive analysis by Lewis et al. (22) of alternatively spliced
mRNA isoforms contained in the EST database demonstrated
that one-third of the genes analyzed produce alternative tran-
scripts that are candidate targets of NMD. As these authors
point out, such a predicted widespread association of altern-
ative splicing and NMD may indicate a need to eliminate a
large number of aberrant mRNAs, or else, could play a func-
tional role in regulating protein expression levels. Our data
also demonstrate that the alternative transcripts of human
ribosomal protein genes are natural targets of NMD and are
probably regulated in levels by a negative feedback network.
We have identified alternative transcript isoforms of the
human rpL3 and rpL12 genes. These isoforms originate from
alternative splicing that causes partial removal of intron 3 in
rpL3, and of intron 1 in rpL12. The resulting mRNA isoforms
carry intronic sequences that contain PTCs, and are stabilized
by NMD inhibition (Figures 1–3).
In addition, we found that the rpL3 intron responsible for
introducing a PTC in the alternative mRNA isoform is con-
served among mammals (human, mouse and bovine species).
In fact, there is a high degree of sequence identity along
the whole intron, with the highest identity occurring in the
region retained consequent to alternative splicing (Figure 4).
Furthermore, the presence of the alternative mRNA isoform
sequence in several cDNA clones of the mouse EST database,
together with the observation that the alternative transcript is
also present in rat PC12 cells, strongly suggests that the spli-
cing event identified in human cells is common to mammals.
Our analysis of aberrant mRNA production by the mouse
rpL12 provides compelling evidence that NMD target mRNA
isoforms are important for gene regulation. In fact, there
was no relevant similarity between human and mouse rpL12
intron 1. However, a BLAST search in the mouse EST data-
base and RT–PCR analysis revealed the expression of an
alternatively spliced, unproductive mRNA rpL12 isoform.
Strikingly, the splicing event generating this isoform occurs
in the intron of the mouse gene corresponding to the human
intron 1 counterpart, and in a region where the alternative
splice site is conserved not withstanding the low degree of
identity.
It is noteworthy that the alternative splicing event leading
to NMD-sensitive transcripts from mammalian rpL3 and
rpL12 is conserved in lower eukaryotes. In fact, in C.elegans
the orthologue genes produce alternatively spliced isoforms
that accumulate in strains in which the NMD pathway is gen-
etically blocked (20). Interestingly, not only the genes targeted
but also the type of alternative splicing has been preserved
through the evolutionary divergence of nematodes and mam-
mals. In fact, in both, alternative isoforms are generated
through the 30 and 50 alternative splice sites in the rpL3 and
rpL12 genes, respectively. Given these findings, it seems
highly unlikely that the unproductive mRNAs are
erroneously generated by the cell. Most probably, their expres-
sion reflects an evolutionarily conserved function that has yet
to be discovered.
It is conceivable that the generation of NMD-targeted
mRNA isoforms has been conserved because coupling of
alternative splicing and NMD might serve to regulate rpL3
and rpL12 expression. In fact, a body of evidence suggests that
NMD can function as a means of post-transcriptional regula-
tion of gene expression. For example, in C.elegans the expres-
sion of the serin/arginine-rich (SR) proteins SRp20 and
SRp30b is modulated by alternative splicing events that pro-
duce two isoforms, one of which contains a PTC and is
degraded by the NMD pathway (31). In humans, the SR pro-
tein SC35 negatively autoregulates its expression via the coup-
ling of modulated alternative splicing and NMD degradation
of a PTC-containing isoform (32). A similar mechanism of
regulation has been reported for the polypyrimidine tract bind-
ing protein (PTB) (33) and for the ATP-binding cassette, sub-
family C, member 4 (ABBC4) (34).
A proposed model for this mechanism of protein expression
down-regulation has been designated ‘regulated unproductive
splicing and translation’ (RUST), a process through which
gene expression can be regulated post-transcriptionally by the
production of splice forms that will be degraded by NMD
rather than translated into protein (35). However, most tran-
scripts may not be subject to RUST. In fact, while some genes
may acquire the ability to alternatively splice to turn off their
expression, the presence of nonsense codons in the alternat-
ively spliced transcript may not be functionally relevant. For
example, many alternatively spliced transcripts could have
acquired nonsense codons simply because there was no selec-
tion pressure to encode a functional protein product. Thus, the
ability of NMD to degrade alternatively spliced transcripts
may be of no regulatory significance in many circumstances.
Given our results on rpL3 and rpL12 mRNA expression, we
asked whether the regulation of mammalian ribosomal protein
expression could be explained by the RUST model. To address
this issue, we investigated whether the splicing pattern was
affected by the endogenous level of the functional r-protein in
the cell. Using an in vivo overexpressing system, we demon-
strate that overexpresssion of rpL3 in PC12 cells alters the
rpL3 gene splicing pattern: the alternatively spliced isoform
is upregulated, whereas the canonically spliced mRNA
decreases. Moreover, the total quantity of rpL3 endogenous
mRNA does not change consequent to protein overexpression
(data not shown). Thus, only the ratio of canonical versus non-
canonical mRNA is altered. These findings suggest that the
level of the L3 protein affects (directly or indirectly) a switch
in splice-site selection.
Our results lend support to and extend a model proposed by
Mitrovich and Anderson (20) for rpL12 in C.elegans. Indeed,
our model predicts that the quantity of free rpL3, unassembled
in ribosomal subunits, acts as a sensor of rpL3 expression
either by down-regulating canonical splicing, or by up-
regulating non-canonical splicing (Figure 7). Under normal
growth conditions, the canonical transcript is preferentially
spliced; but when conditions in the cell lead to an excess of
rpL3, the canonical splicing is inhibited and the splicing is
mainly directed towards the alternative mode. The result of
this event is an increase in the level of alternative mRNA,
which is targeted to NMD, and a consequent reduction in the
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level of the r-protein. This negative feedback would control
the levels of free rpL3 and avoid wasteful production of the
protein. Thus, we propose a regulatory pathway in which the
decision to splice canonically or alternatively, regulated (dir-
ectly or indirectly) by the protein is followed by degradation
of alternative, unproductive mRNA by NMD.
We also investigated whether this regulatory mechanism is
triggered by a general signal activated by the cell upon accu-
mulation of any other ribosomal protein, or whether it occurs
only in response to the rpL3 increase. Our data show that
the alternative splicing of the rpL3 gene is not influenced
by overexpression of another ribosomal protein (rpL12).
Hence, we conclude that the proposed feedback process is
specifically modulated by rpL3.
To our knowledge, this is the first example of post-
transcriptional regulation mediated by alternative splicing
that gives rise to natural NMD targets reported for mammalian
ribosomal protein genes. Although we do not provide experi-
mental evidence for a similar mechanism in the rpL12 gene,
the conserved expression pattern of the human, bovine and
mouse genes indicates that the same regulation mode also
applies to rpL12. In addition, a mechanism similar to the
one we describe for mammalian rpL3 has been reported in
C.elegans for rpL12 and inferred for rpL3 (20). The fact that
the regulatory mechanism of rp gene expression is widely
conserved highlights the relevance of our results.
In conclusion, NMD could be viewed as a new component
of the complex cellular regulation of ribosomal protein genes.
Post-transcriptional feedback loops are known to modulate
the expression of other r-proteins. However, in all previous
cases, excess r-protein led either to inhibition of splicing and
consequent accumulation of unspliced transcript (36,37), or to
destabilization of the cognate mRNA (38). Here we report that
human rpL3 selects the splicing mode rather than triggering
or not splicing. Moreover, we suggest that regulated splicing
associated with the NMD pathway might represent a way to
fine-tune the amount of an r-protein to the appropriate level.
In other words, the NMD pathway might provide a means with
which to lower the threshold of gene expression below what
would otherwise be possible by modulating the transcription
rate alone. Alternatively, or in addition, this type of post-
transcriptional regulation could provide a temporal control
unattainable by transcription factors. However, in C.elegans
(20) and in mammals, the association of splicing and NMD
does not appear to be a general mechanism of regulation
shared by all r-proteins. Given the global regulation network
of ribosomal components, including r-proteins and rRNAs,
we suppose that a mechanism like NMD, which acts only
on coding RNAs, provides an additional level of modulation,
perhaps specifically targeted to the r-proteins that exert extra-
ribosomal functions and, as such, require ultrafine tuning.
The molecular basis of the autoregulation process identified
in this study remains to be established. The striking sequence
conservation of rpL3 intron 3 may indicate that it contains
cis-elements, recognized by a regulatory protein, that are crit-
ical for selecting the type of splicing. Perhaps, as demonstrated
for other ribosomal proteins (i.e. rpL32), the free rpL3 might
be directly involved in modulating splicing of the rpL3 gene
by binding the unprocessed transcript in intron 3. A similar
mechanism could apply to rpL12. In this case, however, the
critical interaction target could be a common secondary struc-
ture assumed by the loosely conserved regions of intron 1.
In fact, preliminary analysis of RNA folding, performed using
the M-FOLD program on human and mouse rpL12 intron 1,
has predicted similar structures for these sequences. It will be
interesting to clarify the significance of the different sequence
conservation in mammals of rpL3 intron 3 and rpL12 intron 1,
and how each intron is functionally involved in the regulated
splicing.
In conclusion, this report casts light on the regulation of
mammalian ribosomal proteins by newly identified molecular
strategies, and supports the concept that the NMD pathway
plays a more prominent role in the regulation of gene expres-
sion than hitherto recognized.
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